ACT in action.

Blanca Morales’ son was sick for four months before she started asking for a transplant, but stricter FDA guidelines around stool banks made the treatment harder to find.

ACT is proud to announce that our collaboration with the University of Minnesota Microbiota Therapeutics Program is partnering with OpenBiome to distribute Intestinal Microbiota Therapeutics to patients suffering from recurrent C. difficile infections. To date, we have treated over 1,500 recurrent C. difficile patients. Now, utilizing OpenBiome’s network of clinical providers across the country, we aim to treat thousands more.

Clostridium difficile infection (CDI) is the most common hospital-acquired infection in the U.S., and has become a global public health issue. The infection can cause a range of gastrointestinal symptoms, which estimates suggest ultimately result in nearly 30,000 deaths every year in the U.S. alone. While the most significant risk factor for CDI is antibiotic treatment, studies in mice by a team at Vanderbilt University School of Medicine now provide new evidence that connects the use of common nonsteroidal anti-inflammatory drugs (NSAID) with increased severity of CDI. Their results also point to the molecular mechanisms that underpin this link.